Financing ·
Taysha Gene Therapies, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC to…
TSHATaysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC to issue and sell 32,500,001 shares of common stock and 833,333 pre-funded warrants at $6.00 per share and $5.999 per warrant respectively. The company estimates net proceeds of approximately $187.4 million, or $215.6 million if the underwriters exercise their option to purchase an additional 5,000,000 shares. Taysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodevelopmental disorders.